Pure Zees recently announced the expansion of its innovative asthma & allergy friendly® mattresses into the U.S. market, unveiling a new U.S. website to help roll out multiple related products through 2020. The Irish-based company has secured coveted certification for their signature infant mattress from both Allergy Standards Limited of Ireland (ASL) and The Asthma and Allergy Foundation of America (AAFA).
Welcome to your February advocacy update. I’m Jenna Riemenschneider, director of Advocacy at the Asthma and Allergy Foundation of America (AAFA). I am pictured above with AAFA board member Renuka Babu Brown and Senator Ed Markey's (D-MA) policy advisor Adam Axler. Over-the-Counter Drug Access and Cleaner Cars Rollbacks AAFA and other members of the Healthy Choices Coalition met with Representative Judy Chu's office. We asked her to co-sponsor the Restoring Access to Medication Act of 2019...
U.S. Senator Tom Carper (D-Del.), top Democrat on the U.S. Senate Environment and Public Works Committee, was joined by 32 Senators in introducing legislation that would put the United States on a path to achieve net-zero greenhouse gas emissions by no later than 2050.
The 2019 new coronavirus (also known at 2019-nCoV) is a hot topic in the news. Now that it has spread to the U.S., you may wonder if you should be concerned. It is a respiratory virus, meaning it affects the lungs, so what do people with asthma need to know?
Flowers, candy, perfume and candles may be common gifts for Valentine’s Day. But if you give them to your loved ones with asthma and allergies, you may give them something you didn’t plan on – triggers that cause symptoms. Instead, give non-traditional asthma and allergy friendly gifts.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.